News

Health Innovation Networks lead national roll out of new kidney care service

16 November 2026

All 15 health innovation networks across England are working together to roll out a successful care model to improve kidney care.

The LUCID – Connecting kidney care programme improves patient outcomes through early detection of chronic kidney disease (CKD), early intervention and optimisation, while maximising productivity and value for money.

An economic analysis commissioned by the Health Innovation Network highlights the massive potential that could be achieved by rolling out the programme across England:

• £69.4 million potential benefits in year one

• £334.9 million potential benefits over five years

• Over five years, an estimated £3.25 return for every £1 invested.

In Hampshire and Isle of Wight we are supporting the spread of the primary care led SPOT CKD (Screening, Prevention, Outreach and Treatment for Health Equity) project, which aligns with the principles of LUCID. SPOT CKD aims to enhance access to care and improve outcomes for people in underserved communities at risk of, or diagnosed with, chronic kidney disease (CKD). We are also exploring approaches that support the Cardiovascular, kidney and metabolic modern service framework to offer holistic assessment and management of patients.

The model bridges the gap between primary and secondary care by integrating management of CKD. It has four main principles:

• LUCID multi-disciplinary team meetings (MDTs) are established, ensuring a more joined-up approach between hospital and GP practice care teams.

• Steps are put in place to identify patients more at risk of kidney disease.

• Training is provided for clinicians, and patients are better informed and able to manage their care.

• Ongoing healthcare management is optimised.

In the UK, over 3m people live with the most severe stages of kidney disease and this is rising rapidly. People with kidney disease face increased risk of heart attack or stroke. The total annual economic burden of kidney disease in the UK is £7.0 billion, with £6.4 billion being direct costs to the NHS – about 3.2% of NHS budgets. (ref: https://www.kidneyresearchuk.org/about-us/policy/health-economics-report/)

For more information visit the Health Innovation East Midlands website.


The original LUCID programme was developed through a Joint Working Agreement between the John Walls Renal Unit at University Hospitals of Leicester NHS Trust and AstraZeneca UK. That Joint Working project has concluded, and AstraZeneca UK has now signed a Memorandum of Understanding with Health Innovation East Midlands to share expertise and insights on the future implementation and scaling of LUCID.

Share


More news

See all news

Need more information?

Contact the communications team:
(023) 8202 0858

Stay connected, sign up for
our monthly newsletter

Sign up now Funding newsletter